Currently out of the existing stock ratings of Andrew Tsai, 28 are a BUY (93.33%), 2 are a HOLD (6.67%).

Andrew Tsai

Work Performance Price Targets & Ratings Chart

Analyst Andrew Tsai, currently employed at JEFFERIES, carries an average stock price target met ratio of 36.67% that have a potential upside of 29.82% achieved within 138 days.

Andrew Tsai’s has documented 69 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RLMD, Relmada Therapeutics at 17-Sep-2024.

Wall Street Analyst Andrew Tsai

Analyst best performing recommendations are on XENE (XENON PHARMACEUTICALS).
The best stock recommendation documented was for XENE (XENON PHARMACEUTICALS) at 8/30/2021. The price target of $28 was fulfilled within 35 days with a profit of $11.09 (65.58%) receiving and performance score of 18.74.

Average potential price target upside

of $27.92 (69.83%) on ITCI (INTRACELLULAR TH).
of $13.92 (61.23%) on XENE (XENON PHARMACEUTICALS).
of $5.91 (35.89%) on ATHA (ATHIRA PHARMA ).

ATHA Athira Pharma ITCI Intracellular Th XENE Xenon Pharmaceuticals ATAI ATAI Life Sciences BV SAGE Sage Therapeutic VTGN VistaGen Therapeutics MRNS Marinus Pharmaceuticals RLMD Relmada Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jason Butler (JMP)